#
|
Title
|
Authors
|
Affiliations
|
Keywords
|
P451
|
Alpha-TEA demonstrates antitumor activity against trastuzumab sensitive and resistant breast cancer
|
Emmanuel Akporiaye1, Mary Disis2, Ekram Gad2, Tobias Hahn1, Brook Cole3, Michael Gough1, Talicia Savage4, Hailing Lu5
|
1Providence Portland Medical Center, Portland, OR, USA 2University of Washington School of Medicine, Seattle, WA, USA 3University of Minnesota, Minneapolis, MN, USA 4Albert Einstein College of Medicine, Bronx, NY, USA 5Immune Design, Seattle, WA, USA
|
Tumor microenvironment | Immune adjuvant | Antibody | Solid tumors
|
P452
|
Defining IL-15 expressing myeloid cells in the tumor microenvironment
|
Figen Beceren-Braun1, Rosa M. Santana Carrero1, Sarai C. Rivas1, Kimberly S. Schluns1
|
1University of Texas MD Anderson Cancer Center, Houston, TX, USA
|
Tumor microenvironment | Monocyte/Macrophage | Cytokine | Gene expression | Inflammation
|
P453
|
Targeted tumor stroma depletion in combination with a whole cell tumor vaccine enhances effector T cell infiltration in a mouse model of pancreatic cancer
|
Alex Blair1, Victoria Kim1, Stephen Muth1, Todd Armstrong1, Sanna Rosengren2, Lei Zheng1
|
1Johns Hopkins Medical Institution, Baltimore, MD, USA 2Halozyme Therapeutics, San Diego, CA, USA
|
Tumor microenvironment | Gene expression | Monocyte/Macrophage | T cell | Solid tumors | Tumor stroma | Vaccine | Tumor infiltrating lymphocytes (TILs)
|
P454
|
Molecular targeted radiotherapy facilitates in situ vaccination in a syngeneic murine melanoma model
|
Peter M Carlson1, Clinton Heinze1, Joseph Grudzinski1, Reinier Hernandez1, Stephen D Gillies2, Hans Loibner3, Alexander L Rakhmilevich1, Mario Otto1, Bryan Bednarz1, Jamey Weichert1, Paul M Sondel1, Zachary S Morris1
|
1University of Wisconsin School of Medicine and Public Health, Madison, WI, USA 2Provenance Biopharmaceuticals, Carlisle, MA, USA 3Apeiron Biologics, Vienna, Austria
|
Regulatory T cell (Treg) | Tumor microenvironment | Targeted therapy | Immune suppression | Vaccine | T cell
|
P455
|
Investigating the specificity and response of a native leukemia-reactive CD8+ T cell clone
|
Xiufen Chen1, Brendan MacNabb1, Emily Curran1, Bruce Blazar2, Justin Kline1
|
1University of Chicago, Chicago, IL, USA 2University of Minnesota, Minneapolis, MN, USA
|
Antigen presenting cells | Immune tolerance | Tumor microenvironment | Leukemia/Lymphoma | Tumor infiltrating lymphocytes (TILs) | Checkpoint blockade
|
P456
|
CDK4 & 6 inhibitor Abemaciclib exerts intrinsic immunomodulatory effects on human T cells in vitro
|
Darin Chin1, Carmine Carpenito1, Nelusha Amaladas1, Linda Chung2, Kirk Staschke2, David Schaer3, Richard Beckmann2, Ruslan Novosiadly1, Michael Kalos1
|
1Eli Lilly & Co, New York, NY, USA 2Eli Lilly & Co, Indianapolis, IN, USA 3Eli Lilly & Co, Brooklyn, NY, USA
|
Biomarkers | Checkpoint blockade | Gene expression | Immune toxicity | Immune tolerance | Costimulation
|
P457
|
Pharmacodynamic activity of MEDI9197, a TLR7/8 agonist, administered intratumorally in subjects with solid subcutaneous or cutaneous tumors
|
Zachary A. Cooper1, Christopher A. Morehouse1, Yuling Wu1, Keith Steele1, David Brucker2, Leo Tseng1, Maria Jure-Kunkel1, Nancy Mueller1, Patricia Ryan1, Juneko Grilley-Olson3, David Hong4, Aurélien Marabelle5, Pamela Munster6, Rahul Aggarwal6, Sandrine Aspeslagh5, Robert G. Dixon3, Manish Patel7, Vivek Subbiah4, Joshua Brody8, Shilpa Gupta7
|
1MedImmune, Gaithersburg, MD, USA 2Definiens, Cambridge, MA, USA 3University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA 4MD Anderson Cancer Center, Houston, TX, USA 5Institut Gustave Roussy, 94800 Villejuif, France 6UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA 7Masonic Cancer Center, Minneapolis, MN, USA 8Mount Sinai (Hess Center for Science and Medicine), New York, NY, USA
|
TLR | Inflammation | Checkpoint blockade | MDSC | Chemokine | Cytokine | T cell | Dendritic cell
|
P458
|
Nitric oxide synthase inhibition results in PDL-1 upregulation and ADAR1 inhibition, triggering immunogenic cell death: an in-vitro and in-vivo analysis
|
Daniel Davila-Gonzalez1, Roberto Rosato1, Wei Qian1, Anthony Kozielski1, Wen Chen1, Dong Soon Choi1, Patrick Tucker1, Jenny Chang1
|
1Houston Methodist, Houston, TX, USA
|
Adoptive immunotherapy | Tumor microenvironment | Checkpoint blockade | Targeted therapy | Antibody | Cytokine | Immune suppression | T cell
|
P459
|
Class IIa HDAC inhibition promotes an anti-tumor macrophage phenotype that induces breast tumor regression and inhibits metastasis
|
Jennifer Guerriero1, Alaba Sotayo1, Holly Ponichtera1, Jessica Castrillon1, Alexandra Pourzia1, Sara Schad1, Shawn Johnson1, Ruben Carrasco1, Suzan Lazo1, Roderick Bronson2, Scott Davis3, Mercedes Lobera3, Michael Nolan3, Anthony Letai1
|
1Dana-Farber Cancer Institute, Boston, MA, USA 2Harvard Medical School, Boston, MA, USA 3GlaxoSmithKline, Cambridge, MA, USA
|
Antigen presenting cells | Costimulation | Myeloid cells | Tumor microenvironment | Monocyte/Macrophage | Solid tumors
|
P460
|
Selenium, the element of the moon, improves immunotherapies on earth
|
Claudia Lennicke1, Shamim Ahmad1, Rajeev Shrimali1, Barbara Seliger2, Youcef Rustum3, John Janik1, Mikayel Mkrtichyan1, Seema Gupta1, Samir Khleif1
|
1Augusta University, Augsuta, GA, USA 2Institute of Medical Immunology, Halle, Germany 3University of Buffalo, Buffalo, NY, USA
|
Tumor microenvironment | Regulatory T cell (Treg) | Vaccine | Tumor evasion | Tumor infiltrating lymphocytes (TILs) | T cell | Solid tumors | Immune suppression | Tumor antigens
|
P461
|
Listeria monocytogenes-based immunotherapies alter the suppressive phenotype of intratumoral regulatory T cells
|
Rachelle E. Kosoff1, Nithya Thambi1, Lauren K. Pettit1, Daniel O. Villarreal1, Kimberly Ramos1, Michael F. Princiotta1, Robert G. Petit1, Sandra M. Hayes1
|
1Advaxis, Inc., Princeton, NJ, USA
|
Tumor microenvironment | Regulatory T cell (Treg) | Tumor infiltrating lymphocytes (TILs) | Vaccine | Immune monitoring | Gene expression
|
P462
|
Ubiquitin-specific Protease 6 (USP6) Oncogene Promotes Immune Cell Recruitment in Sarcoma
|
Ian Henrich1, Laura Quick2, Rob Young2, Andre Oliveira3, Margaret Chou1
|
1University of Pennsylvania, Philadelphia, PA, USA 2Children's Hospital of Pennsylvania, Philadelphia, PA, USA 3Mayo Clinic, Rochester, MN, USA
|
Carcinogenesis | Pediatric tumors | Tumor microenvironment | Chemokine | Cytokine | Solid tumors
|
P463
|
TAM RTKs Facilitate MDSC-mediated Tumor Immunosuppression
|
Alisha Holtzhausen1, William Harris1, Debra Hunter1, Eric Ubil1, Xiaodong Wang1, Douglas Graham2, Stephen Frye1, H. Shelton Earp1
|
1University of North Carolina at Chapel Hill, Chapel Hill, NC, USA 2Emory University, Atlanta, GA, USA
|
Immune tolerance | Myeloid cells | Tumor microenvironment | MDSC
|
P464
|
Use of evofosfamide for targeting immune-suppressive hypoxia in head and neck squamous cell carcinoma
|
Francis Hunter1, Avik Shome1, Way Wong1, Pratha Budhani2, Neil Senzer3, E. Gabriela Chiorean4, Dan Li1, Peter Tsai1, Nooriyah Poonawala1, Purvi Kakadiya1, Maria Kondratyev5, Courtney Lynch1, Cho Rong Hong1, Tet-Woo Lee1, Dennis Kee6, Andrew Macann6, Nicholas McIvor6, Kevin Hicks1, Stefan Bohlander1, Cristin Print1, Stew Kroll7, Charles Hart7, Bradly Wouters5, William Wilson1, Michael Curran2, Stephen Jamieson1
|
1University of Auckland, Auckland, New Zealand 2MD Anderson Cancer Center, Houston, TX, USA 3Mary Crowley Cancer Research Center, Dallas, TX, USA 4Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA 5University Health Network, Toronto, ON, Canada 6Auckland City Hospital, Auckland, New Zealand 7Threshold Pharmaceuticals, San Francisco, CA, USA
|
Tumor microenvironment | Biomarkers | Checkpoint blockade | Targeted therapy | Solid tumors | Radiotherapy | Immune suppression | Clinical trial
|
P465
|
Characterization of immune cells in the pre-metastatic niche in a murine model of rhabdomyosarcoma
|
Sabina Kaczanowska1, Meera Murgai1, Daniel Beury1, Rosandra Kaplan1
|
1National Cancer Institute, Bethesda, MD, USA
|
Pediatric tumors | Tumor microenvironment | Immune contexture
|
P466
|
Rational Design of Immuno-Oncology Biologics with Improved Safety and Efficacy
|
Margaret Karow1, Kurt Jenkins2, Miso Park2, Parker Johnson2, Asaul Gonzalez2, Veronica Flesch2, Tim Miles2, Ulrich Rodeck3, John Williams2
|
1Akriveia Therapeutics, Thousand Oaks, CA, USA 2City of Hope, Duarte, CA, USA 3Thomas Jefferson University, Philadelphia, PA, USA
|
Regulatory T cell (Treg) | Tumor microenvironment | Autoimmunity | Checkpoint blockade | Immune toxicity | Targeted therapy | Antibody | T cell | Tumor infiltrating lymphocytes (TILs) | Solid tumors
|
P467
|
CCR4 antagonists inhibit regulatory T cell (Treg) recruitment and increase effector T cell (Teff) numbers in the tumor microenvironment potentiating an anti-tumor response
|
Oezcan Talay1, Lisa Marshall1, Cesar Meleza1, Maureen Reilly1, Omar Robles1, Mikhail Zibinsky1, Abood Okal1, Jenny McKinnell1, Scott Jacobson1, Erin Riegler2, Sashie Marubayashi1, Emily Karbarz1, David Chian1, Angela Wadsworth1, David Wustrow1, Jordan Fridman2, Paul Kassner1
|
1FLX Bio Inc., South San Francisco, CA, USA 2Formerly at FLX Bio Inc., South San Francisco, CA, USA
|
Chemokine | Tumor microenvironment | Regulatory T cell (Treg) | Immune contexture | Checkpoint blockade | T cell | Tumor infiltrating lymphocytes (TILs) | Immune suppression
|
P468
|
A novel 3D ex vivo platform of fresh patient tumor tissue with intact tumor microenvironment for immuno-oncology drug development and biomarker discovery
|
Melanie Mediavilla-Varela1, Melba Marie Page1, Jenny Kreahling1, Scott Antonia1, Soner Altiok1
|
1Nilogen Oncosystems, Tampa, FL, USA
|
Biomarkers | Checkpoint blockade | Cytokine | Chemokine | Tumor microenvironment | Targeted therapy | Solid tumors | Tumor infiltrating lymphocytes (TILs) | Monocyte/Macrophage | T cell
|
P469
|
Tumor oxygenator OMX reverses multiple modes of immunosuppression, activates anti-tumor immunity and cures as a single agent, and in combination with anti-PD-1 in resistant orthotopic tumors
|
Ana Krtolica1, Natacha Le Moan1, Philberta Leung1, Sarah Ng1, Tina Davis1, Carol Liang1, Jonathan Winger1, Stephen P. L. Cary1
|
1Omniox, Inc., San Carlos, CA, USA
|
Tumor microenvironment | Tumor stroma | Tumor infiltrating lymphocytes (TILs) | Solid tumors | Immune suppression | Checkpoint blockade | Angiogenesis | Regulatory T cell (Treg) | Cytokine | Chemokine
|
P470
|
Tertiary lymphoid organs as a good prognostic indicator following neoadjuvant chemo (radio) therapy for pancreatic cancer
|
Shota Kuwabara1, Takahiro Tsuchikawa1, Yoshitsugu Nakanishi1, Toshimichi Asano1, Takehiro Noji1, Yo Kurashima1, Yuma Ebihara1, Soichi Murakami1, Toru Nakamura1, Keisuke Okamura1, Toshiaki Shichinohe1, Satoshi Hirano1
|
1Hokkaido University Graduate School of Medicine, Sapporo Hokkaido, Japan
|
Biomarkers | Chemotherapy | Tumor microenvironment | Surgery | Solid tumors
|
P471
|
Patterns of immune cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors
|
Katie Leick1, Joel Pinczewski2, Donna Deacon1, Amber Woods1, Marcus Bosenberg3, Victor Engelhard1, Craig Slingluff1
|
1University of Virginia, Charlottesville, VA, USA 2Dorevitch Pathology, North Melbourne, Australia 3Yale University, New Haven, CT, USA
|
Tumor antigens | Tumor infiltrating lymphocytes (TILs) | Immunoscore | Neoantigens | Solid tumors | Tumor microenvironment
|
P472
|
DARPin®-based fibroblast activation protein-targeted agonists of 4-1BB and OX40 co-stimulate T-cells in a Fc-receptor-independent, tumor-restricted manner
|
Alexander Link1, Julia Hepp1, Ulrike Fiedler1, Christian Reichen1, Clara Metz1, Alexander Titz1, Ivana Tosevski1, Joanna Taylor1, Zita Arany1, Laurent Juglair1, Patricia Schildknecht1, Yvonne Kaufmann1, Denis Villemagne1, Simon Fontane1, Ralph Bessey1, Christof Zitt1, Keith Dawson1, Dan Snell1, Daniel Steiner1, Michael Stumpp1, Victor Levitsky1
|
1Molecular Partners AG, Schlieren-Zürich, Switzerland
|
Costimulation | Immune toxicity | Targeted therapy | Tumor stroma | Immune suppression | Tumor infiltrating lymphocytes (TILs)
|
P473
|
Immuno-oncological efficacy of RXDX-106, a novel TAM (TYRO3, AXL, MER) family small molecule kinase inhibitor
|
Erin Lew1, Yumi Yokoyama1, Colin Walsh1, Jack Lee1, Joanne Oh1, Elizabeth Tindall1, Robin Navarez1, Amy Dilberto1, Heather Ely1, Ruth Seelige2, Amanda Albert1, Jack Bui2, Gary Li1
|
1Ignyta, Inc, San Diego, CA, USA 2University of California, San Diego, San Diego, CA, USA
|
Tumor microenvironment | Monocyte/Macrophage | T cell | Tumor infiltrating lymphocytes (TILs) | Targeted therapy
|
P474
|
Gene Expression in MHC II Pathway May Predict Triple Negative Breast Cancer Prognosis
|
Amy Zhao1, Gavin Bond1, Katherine Varley2, Andres Forero-Torres3, Albert LoBuglio3, Dongquan Chen3
|
1University of Pennsylvania, Philadelphia, PA, USA 2University of Utah, Salt Lake City, UT, USA 3University of Alabama at Birmingham, Birmingham, AL, USA
|
Bioinformatics | Biomarkers | Tumor microenvironment | Gene expression | T cell | Tumor infiltrating lymphocytes (TILs) | Antigen presenting cells
|
P475
|
Profiling Immune Infiltration of Glioblastoma
|
Camilo Fadul1, Craig Slingluff1, Ileana Mauldin1
|
1University of Virginia, Charlottesville, VA, USA
|
Tumor microenvironment | Tumor infiltrating lymphocytes (TILs) | Biomarkers | Immune tolerance
|
P476
|
Targeting the IDO/TDO Pathway through Degradation of the Immunosuppressive Metabolite Kynurenine and Inhibition of the Downstream AHR Pathway
|
Karen McGovern1, X. Michelle Zhang1, Everett Stone3, Todd Triplett3, Kendra Garrison3, Silvia Coma1, Luis Felipe Campesato2, Meghan Walsh1, Jeremy Tchaicha1, Candice Lamb3, Christos Karamitros3, John Blazek3, Taha Merghoub2, Jedd Wolchok2, George Georgiou3, Mark Manfredi1
|
1Kyn Therapeutics, Cambridge, MA, USA 2Memorial Sloan Kettering Cancer Center, New York, NY, USA 3University of Texas, Austin, TX, USA
|
Immune suppression | Metabolism | Tumor microenvironment | Tumor infiltrating lymphocytes (TILs) | T cell | Checkpoint blockade | Gene expression
|
P477
|
Novel effector phenotype of Tim3+ regulatory T cells leads to enhanced suppressive function in head and neck cancer patients
|
Zhuqing Liu1, Elizabeth McMichael2, Gulidanna Shayan3, Jing Li3, Rghvendra Srivastava2, Lawrence Kane2, Robert Ferris2
|
1Tongji University, Shanghai, China 2University of Pittsburgh, Pittsburgh, PA, USA 3Tsinghua University, Beijing, China
|
Tumor microenvironment | T cell | Immune suppression
|
P478
|
Formation and functional associations of CD49a-, CD49b- and CD103-expressing CD8 T cell populations in human metastatic melanoma
|
Marit Melssen1, Walter Olson1, Nolan Wages1, Ciara Hutchison1, Ileana Mauldin1, Cornelis Melief2, Timothy Bullock1, Victor Engelhard1, Craig Slingluff, Jr1
|
1University of Virginia, Charlottesville, VA, USA 2ISA Pharmaceuticals, Leiden, Netherlands
|
Tumor infiltrating lymphocytes (TILs) | Tumor microenvironment | T cell lineages | Tumor stroma | Cytokine | T cell | Solid tumors
|
P479
|
MPL-5821, an ESM™-p38 MAPK Inhibitor, modulates macrophage plasticity leading to enhanced IL-12p70 and IFN gamma, reduced IL-10 and the reversal of macrophage induced T-cell suppression.
|
Martin Perry1, David Moffat1, Justyna Rzepecka2, Lucia Janicova2, Anastasia Nika2, Darryl Turner2, Clare Doris2, Stephen Anderton2
|
1Macrophage Pharma Limited, Windsor, United Kingdom 2Aquila BioMedical Limited, Edinburgh, United Kingdom
|
Antigen presenting cells | Myeloid cells | Tumor microenvironment | Targeted therapy | Chemokine | Cytokine | Immune suppression | Monocyte/Macrophage | T cell | Inflammation
|
P480
|
Tumor infiltrating T regulatory cells in head and neck cancer patients treated with cetuximab demonstrate increased inhibitory receptors and survival.
|
Jessica Moskovitz1, Tullia Bruno1, Robert Ferris1, Dario Vignali1
|
1University of Pittsburgh, Pittsburgh, PA, USA
|
Immune tolerance | Tumor microenvironment | Tumor evasion | Tumor infiltrating lymphocytes (TILs) | T cell | Solid tumors | Regulatory T cell (Treg) | Surgery
|
P481
|
Non-oncogenic Acute Viral Infection Modulates the Innate Immune Response and Reduces Tumor Growth in Hosts with Established Cancer
|
Jenna Newman1, Charles Brent Chesson1, Andrew Zloza1
|
1Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
|
MDSC | Tumor microenvironment | Solid tumors | Inflammation
|
P482
|
Somatic TP53 mutations alter the immune micro-environment after chemotherapy in breast cancer
|
Mellissa Nixon1, M. Valeria Estrada2, Susan Opalenik1, Donna Hicks3, Michael Korrer1, Mark Pilkinton1, Melinda Sanders1, Roberto Salgado4, Simon Mallal1, Young Kim1, Rebecca Cook3, Carlos Arteaga1, Justin Balko1
|
1Vanderbilt University Medical Center, Nashville, TN, USA 2UC San Diego, La Jolla, CA, USA 3Vanderbilt University, Nashville, TN, USA 4Institut Jules Bordet, Brussels, Belgium
|
Bioinformatics | Chemotherapy | Biomarkers | Chemokine | Gene expression | Solid tumors | Tumor infiltrating lymphocytes (TILs) | Tumor microenvironment | Cytokine | T cell
|
P483
|
A novel non-competitive and non-brain penetrant adenosine A2A receptor antagonist designed to reverse adenosine-mediated suppression of anti-tumor immunity
|
Erica Houthuys1, Reece Marillier1, Théo Deregnaucourt1, Margreet Brouwer1, Romain Pirson1, Joao Marchante1, Paola Basilico1, Shruthi Prasad1, Julie Preillon1, Anne-Catherine Michaux1, Kim Frederix1, Annelise Hermant1, Florence Nyawouame1, Charlotte Moulin1, Vanesa Bol1, Bruno Gomes1, Florence Lambolez1, Véronique Bodo1, Jakub Swiercz1, Gregory Driessens1, Noémie Wald1, Chiara Martinoli1, Michel Detheux1, Christophe Quéva1, Stefano Crosignani1
|
1iTeos Therapeutics, Gosselies, Belgium
|
Tumor microenvironment | Immune suppression | Tumor infiltrating lymphocytes (TILs) | Tumor evasion
|
P484
|
A novel metabolic therapeutic that harnesses the anti-tumor immune response
|
Dayana Rivadeneira1, Nicole Scharping1, Greg Delgoffe1
|
1University of Pittsburgh, Pittsburgh, PA, USA
|
T cell | Tumor microenvironment | Immune suppression | Metabolism | Tumor infiltrating lymphocytes (TILs)
|
P485
|
Use of the NanoString Gene Expression Profiling Platform to Capture the Immunological Status of the Leukemia Microenvironment
|
Jayakumar Vadakekolathu1, Tasleema Patel2, Stephen Reeder1, Heidi Schaarschmidt3, Marc Schmitz4, Martin Bornhäuser3, Sarah Warren5, Tressa Hood5, Patrick Danaher5, Alessandra Cesano5, Joseph M. Beechem5, A. Graham Pockley1, Sarah Tasian2, Sergio Rutella1
|
1Nottingham Trent University, Nottingham, United Kingdom 2Children's Hospital of Philadelphia, Philadelphia, PA, USA 3University Hospital Carl Gustav Carus, Dresden, Germany 4Medical Faculty Carl Gustav Carus, Dresden, Germany 5NanoString Technologies, Inc., Seattle, WA, USA
|
Immune monitoring | Immune contexture | Immune tolerance | Inflammation | Pediatric tumors | Tumor microenvironment | Biomarkers | Leukemia/Lymphoma
|
P486
|
Utilization of dual IHC and quantitative image analysis techniques to evaluate LAG-3-positive T cells in the tumor microenvironment of NSCLC tissue
|
Malik Khenkhar1, Philipp Uhlig1, Nickels Winkler1, Hartmut Juhl1, Alison Bigley2, Lorcan Sherry2
|
1Indivumed GmbH, Hamburg, Germany 2OracleBio Limited, Glasgow, United Kingdom
|
Immune contexture | Tumor microenvironment | Checkpoint blockade | Tumor stroma | Tumor infiltrating lymphocytes (TILs) | T cell | Biomarkers | Targeted therapy | Immune tolerance | Immune monitoring
|
P487
|
Multiplex immunofluorescence evaluation of an immune cell marker panel in the tumor microenvironment of NSCLC tissue using tailored analysis of multi-spectral image component data
|
Richard Bystry1, Edward Durley1, Lee Dawson1, Rebecca Houliston1, Alison Bigley2, Lorcan Sherry2
|
1Asterand Bioscience, Royston, United Kingdom 2OracleBio Limited, Glasgow, United Kingdom
|
Inflammation | Tumor microenvironment | Immune contexture | Biomarkers | Immune monitoring | Tumor stroma | Tumor infiltrating lymphocytes (TILs) | T cell | Regulatory T cell (Treg) | T cell lineages
|
P488
|
Single-cell RNA sequencing of CD8+ T cells to prioritize immunotherapy combinations
|
Yashaswi Shrestha1, Michael Kuziora1, Lydia Greenlees1, Brandon Higgs1, Katie Streicher1, Rajiv Raja1, Koustubh Ranade1
|
1MedImmune, Gaithersburg, MD, USA
|
Inflammation | Checkpoint blockade | Chemokine | Cytokine | T cell | Targeted therapy | Biomarkers
|
P489
|
Studying the cellular heterogeneity and spatial arrangement of immune cells in FFPE sections of Hodgkin Lymphoma and normal lymph node using a highly multiplexed Imaging Mass Cytometry
|
Mohan Singh1, Parvesh Chaudhry1, Erik Gerdtsson1, Lisa Harton1, James Hicks1, Peter Kuhn1, Wendy Cozen1, Imran Siddiqi1, Akil Merchant1
|
1University of Southern California, Los Angeles, Los Angeles, CA, USA
|
Tumor microenvironment | Regulatory T cell (Treg) | Proteomics | T cell | B cell | Tumor infiltrating lymphocytes (TILs)
|
P490
|
PSMA-specific CARTyrin T-Stem Cell Memory Therapy Eliminates Solid Tumor in Subcutaneous Prostate Cancer Model
|
Jenessa B. Smith1, Rebecca Codde1, Yening Tan1, Burton E. Barnett1, David Hermanson1, Srinivas Rengarajan1, Eric M. Ostertag1, Devon J. Shedlock1
|
1Poseida Therapeutics, San Diego, CA, USA
|
Adoptive immunotherapy | T cell lineages | Tumor microenvironment | Targeted therapy | Tumor antigens | T cell | Solid tumors | CAR T cells
|
P491
|
Alerting the immune system by removing epigenetic silencing of TH1 chemokines
|
Heather Sonnemann1, Amber Giles1, Jinkyu Jung1, Caitlin Reid1, Marsha-Kay Hutchinson1, Deric Park1, Mark Gilbert1
|
1NIH, NCI, Bethesda, MD, USA
|
Tumor infiltrating lymphocytes (TILs) | Cytokine | Tumor microenvironment
|
P492
|
Galectin-3 inhibition with GR-MD-02 synergizes with agonist anti-OX40 mAb therapy leading to reduced immune suppression and improved overall survival
|
Elizabeth Sturgill1, Stephanie Linch1, Courtney Mick1, Melissa Kasiewicz1, William Redmond1
|
1Providence Portland Medical Center, Portland, OR, USA
|
Myeloid cells | Costimulation | Tumor microenvironment | MDSC | Tumor infiltrating lymphocytes (TILs) | Solid tumors | Immune suppression | T cell
|
P493
|
LTX-315: A first-in-class oncolytic peptide that reshapes the tumor microenvironment
|
Baldur Sveinbjørnsson1, Ketil Camilio2, Meng-Yui Wang2, Janne Nestvold3, Gunhild Mælandsmo2, Gunnar Kvalheim2, Øystein Rekdal1
|
1Lytix Biopharma, Oslo, Norway 2Radiumhospitalet, Oslo, Norway 3Rikshospitalet, Oslo, Norway
|
Chemotherapy | Tumor microenvironment | Checkpoint blockade | Tumor antigens | Chemokine | Tumor infiltrating lymphocytes (TILs)
|
P494
|
Reversal of Adenosine-Mediated Immune Suppression by AB421, a Potent and Selective Small-Molecule CD73 Inhibitor
|
Joanne BL Tan1, Annette Becker1, Daniel DiRenzo1, Kristen Zhang1, Ada Chen1, Rhiannon Thomas-Tran1, Joel Beatty1, Debashis Mandal1, Guifen Xu1, Steve Young1, Matthew Walters1, Ulrike Schindler1, Jay Powers1
|
1Arcus Biosciences, Hayward, CA, USA
|
Tumor microenvironment | Immune suppression
|
P495
|
Separate molecular pathways mediate anti-tumor versus tumor-promoting Aspects of dsRNA signaling in cancer microenvironments
|
Marie-Nicole Theodoraki1, Saumendra Sarkar1, Ravi Muthuswamy1, Jamie Voyten1, Robert Edwards2, David Bartlett1, Kalinski Pawel1
|
1University of Pittsburgh, Pittsburgh, PA, USA 2Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA
|
Immune suppression | Tumor microenvironment | TLR
|
P496
|
Degradation of hyaluronan (HA) by PEGPH20 promotes anti-tumor immunity and enhances the effect of checkpoint blockade in an HA-accumulating mouse syngeneic tumor model
|
Benjamin J Thompson1, Renee Clift1, Trevor B Kimbler1, Jesse D Bahn1, Chunmei Zhao1, Barbara Blouw1, Curtis B Thompson1, Sanna Rosengren1
|
1Halozyme, San Diego, CA, USA
|
Tumor microenvironment | Tumor stroma | Immune suppression | Tumor infiltrating lymphocytes (TILs) | Checkpoint blockade | Immune contexture
|
P497
|
Tumor microenvironment immune gene signature asscoiated with axicabtagene ciloleucel (axi-cel, KTE-C19), an anti-CD19 chimeric antigen receptor (CAR) T cell, in a multicenter trial (ZUMA-1)
|
John Rossi1, Jérôme Galon2, Sarah Turcan2, Corinne Danan2, Frederick Locke3, Sattva Neelapu4, David Miklos5, Nancy Bartlett6, Caron Jacobson7, Ira Braunschweig8, Olalekan Oluwole9, Tanya Siddiqi10, Yi Lin11, John Timmerman12, Patrick Reagan13, Lazaros Lekakis14, Sherryonne Unabia1, William Go1, Jeff Wiezorek1, Adrian Bot1
|
1Kite Pharma, Santa Monica, CA, USA 2HalioDx, Marseille, France 3Moffitt Cancer Center, Tampa, FL, USA 4MD Anderson Cancer Center, Houston, TX, USA 5Stanford University School of Medicine, Stanford, CA, USA 6Washington University Medical School, Saint Louis, MO, USA 7Dana-Farber Cacner Institute, Boston, MA, USA 8Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA 9Vanderbilt-Ingram Cancer Center, Nashville, TN, USA 10City of Hope National Medical Center, Duarte, CA, USA 11Mayo Clinic, Rochester, MN, USA 12UCLA David Geffen School of Medicine, Santa Monica, CA, USA 13University of Rochester Medical Center, Rochester, NY, USA 14University of Miami Health System, Sylvester Comprehensive Care Center, Miami, FL, USA
|
CAR T cells | Biomarkers | T cell | Tumor microenvironment | Adoptive immunotherapy | Inflammation | Immune contexture
|
P498
|
AB928, a dual antagonist of the A2aR and A2bR adenosine receptors for the treatment of cancer
|
Matthew Walters1, Daniel DiRenzo1, Joanne Tan1, Ulrike Schindler1, Dana Piovesan1, Devika Ashok1, Tim Park1, Nell Narasappa1, Fangfang Yin1, Wan Hsin Lim1, Stefan Garrido-Shaqfeh1, Jenna Jeffrey1, Laurent Debien1, Brandon Rosen1, Ehesan Sharif1, Dillon Miles1, Manmohan Leleti1, Juan Jaen1, Jay Powers1
|
1Arcus Biosciences, Hayward, CA, USA
|
Tumor microenvironment | T cell | Myeloid cells | Monocyte/Macrophage
|
P499
|
Expression pattern and prognostic value of IL-36g in colorectal cancer
|
Aliyah M Weinstein1, Nicolas A Giraldo2, Catherine Julie3, Laetitia Lacroix2, Florent Petitprez2, Jean-François Emile3, Wolf H Fridman2, Walter J Storkus1, Catherine Sautès-Fridman2
|
1University of Pittsburgh, Pittsburgh, PA, USA 2UMR_S1138, Centre de Recherche des Cordeliers, Paris, France 3Hopital Ambroise Paré, Boulogne, France
|
Tumor microenvironment | Tumor stroma | Tumor infiltrating lymphocytes (TILs) | Monocyte/Macrophage | Dendritic cell | Cytokine | Clinical study | Biomarkers | T cell | Myeloid cells
|
P500
|
CD73 blockade restores the abscopal response to radiation therapy and anti-CTLA-4 in cGAS-deficient tumors
|
Erik Wennerberg1, Claire Vanpouille-Box1, Silvia Chiara Formenti1, Sandra Demaria1
|
1Weill Cornell Medicine, New York, NY, USA
|
Antigen presenting cells | Dendritic cell | Tumor microenvironment | Checkpoint blockade | Immune suppression | Radiotherapy | Tumor infiltrating lymphocytes (TILs) | Vaccine
|
P501
|
Involvement of local renin-angiotensin system in immunosuppression of tumor microenvironment and its modulation for augmentation of cancer immunotherapy
|
Tomonori Yaguchi1, Kenta Nakamura2, Kenji Morii1, Yutaka Kawakami1
|
1Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan 2Shinshu University School of medicine, Matsumoto, Nagano, Japan
|
Tumor evasion | Tumor stroma | Immune tolerance | Tumor microenvironment | Checkpoint blockade | MDSC
|
P502
|
IDO1, an immune checkpoint with distinct mechanisms and prognostic significance in glioblastoma
|
Lijie Zhai1, Derek Wainwright1, Erik Ladomersky1, Carlos Dostal2, Kristen Lauing1, Robert McCusker2, David Binder3, Meijing Wu1, Matthew Genet1, Galina Gritsina1, Balaz Gyorffy4, Priscilla Brastinanos5, Jeffrey Sosman1, Craig Horbinski1, David James1, Roger Stupp1, Francis Giles1
|
1Northwestern University Feinberg School of Medicine, Chicago, IL, USA 2University of Illinois at Urbana-Champaign, Urbana, IL, USA 3University of Colorado School of Medicine, Aurora, CO, USA 4Semmelweis University, Budapest, Hungary 5Massachusetts General Hospital, Boston, MA, USA
|
Immune tolerance | Tumor infiltrating lymphocytes (TILs) | Tumor microenvironment
|
P503
|
Comprehensive characterization of immune microenvironment of cholangiocarcinoma
|
Tao Xia1, Dwayne Thomas1, Linda Chen1, Qingfeng Zhu1, Jin He1, Robert Anders1, Shafat Quadri2, Elaine Pinherio2, Adrian Murphy1, Lei Zheng1
|
1Johns Hopkins University School of Medicine, Baltimore, MD, USA 2Merck, Merck, NJ, USA
|
Biomarkers | Myeloid cells | Tumor microenvironment | Immune suppression | Solid tumors | T cell | Tumor infiltrating lymphocytes (TILs) | Checkpoint blockade
|